Schott Pharma AG KGaASHTPY -42.88%64 ROC (Joel Greenblatt) % is 22.07% as of Mar. 2026, which is 37% below its 10-year median of 34.92. GuruFocus rates SHTPY with a GF Score™ of 64/100 and a GF Value™ of $7.02. The stock has 2 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 77.62% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Schott Pharma AG KGaA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 22.07%.
The historical rank and industry rank for Schott Pharma AG KGaA's ROC (Joel Greenblatt) % or its related term are showing as below:
SHTPY'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 26.23 Med: 34.92 Max: 41.57
Current: 26.23
During the past 6 years, Schott Pharma AG KGaA's highest ROC (Joel Greenblatt) % was 41.57%. The lowest was 26.23%. And the median was 34.92%.
SHTPY's ROC (Joel Greenblatt) % is ranked better than 77.62% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.035
vs SHTPY: 26.23
Schott Pharma AG KGaA's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -7.20% per year.
Schott Pharma AG KGaA (OTCPK:SHTPY) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Schott Pharma AG KGaA ROC (Joel Greenblatt) % Related Terms
Schott Pharma AG KGaA ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA ROC (Joel Greenblatt) % Chart
SHTPY vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's ROC (Joel Greenblatt) % falls into.
Schott Pharma AG KGaA ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 22.07% mean?
Schott Pharma AG KGaA (SHTPY) has a ROC (Joel Greenblatt) % of 22.07% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Schott Pharma AG KGaA and its competitors. This is 37% below median its historical median of 34.92. Over the past decade, Schott Pharma AG KGaA's ROC (Joel Greenblatt) % has ranged from 26.23 to 41.57. According to the industry distribution chart, Schott Pharma AG KGaA ranks #188 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 22.4%.
Is Schott Pharma AG KGaA's ROC (Joel Greenblatt) % too high?
Schott Pharma AG KGaA's current ROC (Joel Greenblatt) % of 22.07% is 37% below median its 10-year median of 34.92. Over the past 10 years, this metric has ranged from a low of 26.23 to a high of 41.57. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.04. Schott Pharma AG KGaA's value of 22.07% is 447% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #188 out of 840 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #188 out of 840 companies for ROC (Joel Greenblatt) %. This places Schott Pharma AG KGaA in the top 22% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.04. Schott Pharma AG KGaA's value of 22.07% is 447% above this benchmark. Historically, Schott Pharma AG KGaA's own ROC (Joel Greenblatt) % has ranged from 26.23 to 41.57 over the past decade. While the company's 10-year median is 34.92 vs. the industry median of 4.04, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.04, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current ROC (Joel Greenblatt) % of 22.07% is 447% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current ROC (Joel Greenblatt) % is 22.07%, which is 37% below median its own 10-year median of 34.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current ROC (Joel Greenblatt) % of 22.07%. The stock's GF Value™ is $7.02, compared to a current price of $4.37 — trading 37.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 22.07%, which is 37% below median its 10-year median of 34.92 and 447% above the Medical Devices & Instruments industry median of 4.04. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current ROC (Joel Greenblatt) % is 22.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.
Key valuation signals for SHTPY:
ROC (Joel Greenblatt) %: 22.07% (37% below median its 10-year median of 34.92)
GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
Industry Position: 447% above the Medical Devices & Instruments median (#188 of 840)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score
Get the complete analysis for SHTPY
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
